Incyte (Nasdaq: INCY) today announced that multiple abstracts highlighting data from clinical trials of medicines that are being developed in-house and through partnerships with Novartis, MorphoSys and Takeda will be presented at the upcoming 2020 American Society of Clinical Oncology Virtual Meeting (ASCO20; May 29 May 31); and at the virtual 25th Congress of the European Hematology Association (EHA25; June 11 14).
"We are pleased to have virtual platforms such as ASCO20 and EHA25 to continue sharing important data with the scientific community in a timely manner," said Steven Stein, M.D., Chief Medical Officer, Incyte. "These data demonstrate the strength of our broad oncology portfolio and our partnerships; and reinforce our commitment to finding solutions that can help meet patients needs."
Key abstracts accepted by ASCO and EHA include:
ASCO Abstracts
Oral, poster discussion and poster sessions, as well as track-based clinical science symposia, accepted for presentation at ASCO will be available on demand beginning Friday, May 29, 2020, 8:00 AM ET.
Oral Presentations
Capmatinib in Patients with High-Level MET-Amplified Advanced Non-Small Cell Lung Cancer (NSCLC): Results from the Phase 2 GEOMETRY mono-1 Study (Abstract #9509, Session: MET Mutations: The Meat of the Matter)1
Interim Analysis (IA) of OPTIC: A Dose-Ranging Study of Three Ponatinib (PON) Starting Doses (Abstract #7502, Session: Hematologic MalignanciesLeukemia, Myelodysplastic Syndromes, and Allotransplant)2
E-Poster Presentations
An Independent Review of Arterial Occlusive Events (AOEs) in the Ponatinib (PON) Phase 2 PACE Trial (NCT01207440) in Patients (pts) with Ph+ Leukemia (Abstract #7550, Session: Hematologic MalignanciesLeukemia, Myelodysplastic Syndromes, and Allotransplant)2
Re-MIND Study: A Propensity Score-Based 1:1 Matched Comparison of Tafasitamab + Lenalidomide (L-MIND) Versus Lenalidomide Monotherapy (Real-World Data) in Transplant-Ineligible Patients with Relapsed/Refractory (r/r) Diffuse Large B-cell Lymphoma (DLBCL) (Abstract #8020, Session: Hematologic MalignanciesLymphoma and Chronic Lymphocytic Leukemia)3
Safety and Efficacy of Pemigatinib Plus Pembrolizumab Combination Therapy in Patients (pts) with Advanced Malignancies: Results from FIGHT-101, an Open-Label Phase 1/2 study (Abstract #3606, Session: Developmental TherapeuticsMolecularly Targeted Agents and Tumor Biology)
Capmatinib in Patients with METex14-Mutated or High-Level MET-Amplified Advanced Non-Small-Cell Lung Cancer (NSCLC): Results from Cohort 6 of the Phase 2 GEOMETRY mono-1 study (Abstract #9520, Session: Lung CancerNon-Small Cell Metastatic)1
Pan-Cancer Analysis of FGFR1-3 Genomic Alterations to Reveal a Complex Molecular Landscape (Abstract #3620, Session: Developmental TherapeuticsMolecularly Targeted Agents and Tumor Biology)
EHA Abstracts
Oral abstract presentations and e-posters accepted for presentation at EHA will be available on the on-demand Virtual Congress platform beginning Friday, June 12, 2020, at 8:30 AM CEST.
Oral Presentations
Addition of Parsaclisib, a PI3K inhibitor, in Patients with Suboptimal Response to Ruxolitinib (Rux): A Phase 2 Study in Patients (Pts) with Myelofibrosis (MF) (Abstract #S216, Session: Novel Therapies and Pitfalls in MPN)
Ruxolitinib Versus Best Available Therapy in Patients with Steroid-Refractory Acute Graft-Versus-Host Disease: Overall Response Rate by Baseline Characteristics in the Randomized Phase 3 REACH2 Trial (Abstract #S255, Session: Stem Cell Transplantation Clinical: Graft-Versus-Host Disease)1
GRAVITAS-301: A Randomized, Double-Blind Phase 3 Study of Itacitinib or Placebo in Combination with Corticosteroids for Initial Treatment of Patients with Acute Graft-Versus-Host Disease (Abstract #S256, Session: Stem Cell Transplantation Clinical: Graft-Versus-Host Disease)
Interim Analysis from the OPTIC Trial, a Dose-Ranging Study of 3 Starting Doses of Ponatinib (Abstract #S172, Session: Chronic Myeloid Leukemia (CML) Clinical)2
Re-MIND Study: Comparison of Tafasitamab + Lenalidomide (L-Mind) vs Lenalidomide Monotherapy (Real-World Data) in Transplant-Ineligible Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (Abstract #S238, Aggressive Lymphomas: Observational Studies)3
Story continues
E-Poster Presentations
Real-World Survival in Elderly Patients with Myelofibrosis in the United States: Ruxolitinib Exposed vs Unexposed (Abstract #EP1124, Session: Myeloproliferative Neoplasms Clinical)
Real-World Survival in Elderly Patients with Myelofibrosis in the United States: Pre- vs Post-Ruxolitinib Approval (Abstract # EP1120, Session: Myeloproliferative Neoplasms Clinical)
Machine-Learning to Predict Hydroxyurea (HU) Failure and Incidence of Thromboembolic Events (TEs) with HU vs Ruxolitinib Switch Therapy in Polycythemia Vera Patients (Abstract #EP1117, Session: Myeloproliferative Neoplasms Clinical)1
Patient-Reported Physical, Emotional and Economic Impact of Myeloproliferative Neoplasms in an Expansion of the MPN Landmark Survey (Abstract #EP1112, Session: Myeloproliferative Neoplasms Clinical)1
Ruxolitinib in PV Patients Resistant and/or Intolerant to Hydroxyurea: Interim Analysis of a European Multi-Centric Observational Study (Abstract #EP1115, Session: Myeloproliferative Neoplasms Clinical)1
Treatment and Disease Management Practices in Patients with MPNs in 6 Countries: An Expansion of the MPN Landmark Survey (Abstract #EP1123, Session: Myeloproliferative Neoplasms Clinical)1
Retrospective Independent Review of Arterial Occlusive Events (AOEs) in the Phase 2 PACE Trial of Ponatinib in Philadelphia Chromosome Positive (Ph+) Leukemia (Abstract #EP759, Session: Chronic Myeloid Leukemia (CML) Clinical)2
The RealLife Study Evaluating the Efficacy and Safety of Ponatinib "Topase" Reveals Induction of Deep Molecular Responses in a Cohort of 75 TKI-Resistant or Intolerant patients with CML (Abstract #EP765, Session: Chronic Myeloid Leukemia (CML) Clinical)
Combination of Tafasitamab (MOR208) and Lenalidomide Enhances Tumor Cell Death of B-cell Lymphoma in Vitro (Abstract #EP1343, Session: Lymphoma Biology & Translational Research)3
Long-Term Outcomes from the Phase II L-MIND Study of Tafasitamab (Mor208) Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (Abstract #EP1201, Session: Aggressive Non-Hodgkin Lymphoma - Clinical)3
Expression of CD19 Antigen on Chronic Lymphocytic Leukemia Cells After Tafasitamab (Anti-CD19) Treatment: Phase I Trial Data (Abstract #EP671, Chronic Lymphocytic Leukemia and Related Disorders - Biology & Translational Research)3
For full session details and data presentation listings, please see the ASCO20 (https://meetinglibrary.asco.org) and EHA25 (https://learningcenter.ehaweb.org/eha) online programs.
About IncyteIncyte is a Wilmington, Delaware-based, global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of proprietary therapeutics. For additional information on Incyte, please visit Incyte.com and follow @Incyte.
Forward-Looking StatementsExcept for the historical information set forth herein, the matters set forth in this press release, including statements regarding the presentation of data from the Companys or partner companys ongoing clinical development pipeline, and whether or when any development compounds will be approved or commercially available for use in humans anywhere in the world outside of the already approved indications in specific regions, its presentation plans for the upcoming ASCO and EHA meetings and its goal of improving the lives of patients, contain predictions, estimates and other forward-looking statements.
These forward-looking statements are based on the Companys current expectations and subject to risks and uncertainties that may cause actual results to differ materially, including unanticipated developments in and risks related to: unanticipated delays; further research and development and the results of clinical trials possibly being unsuccessful or insufficient to meet applicable regulatory standards or warrant continued development; the ability to enroll sufficient numbers of subjects in clinical trials; determinations made by the FDA; the Companys dependence on its relationships with its collaboration partners; the efficacy or safety of the Companys products and the products of the Companys collaboration partners; the acceptance of the Companys products and the products of the Companys collaboration partners in the marketplace; market competition; sales, marketing, manufacturing and distribution requirements; greater than expected expenses; expenses relating to litigation or strategic activities; and other risks detailed from time to time in the Companys reports filed with the Securities and Exchange Commission, including its Form 10-K for the year ended March 31, 2020. The Company disclaims any intent or obligation to update these forward-looking statements.
1Novartis-sponsored; 2Takeda-sponsored; 3MorphoSys-sponsored
View source version on businesswire.com: https://www.businesswire.com/news/home/20200514005695/en/
Contacts
Media Catalina Loveman+1 302 498 6171cloveman@incyte.com
Investors Michael Booth, DPhil+1 302 498 5914mbooth@incyte.com
Go here to see the original:
Data from Incytes Oncology Portfolio Accepted for Presentation at the ASCO and EHA Virtual Meetings - Yahoo Finance
- Japan Stem Cells Market to be at Forefront by 2028 - November 24th, 2022
- Mice Model Technologies Market Outlook, Competitive Landscape and Forecasts to 2031 - openPR - October 13th, 2022
- Cell & Tissue Preservation Market Size will Observe Lucrative Surge by the End 2031 - openPR - October 13th, 2022
- PRP and PRF in Cosmetics Market Growth Opportunities Analysis Report - openPR - October 13th, 2022
- Orthobiologics Market to Receive Overwhelming Hike in Revenues by 2031 - openPR - October 13th, 2022
- Stem Cells Market is Expected to Grow with High Probability Business Opportunity by 2028 - Digital Journal - October 4th, 2022
- External Beam Radiation Therapy Market: Growing Awareness about Early Detection and Diagnosis of various Cancer Types to Drive the Market - BioSpace - September 16th, 2022
- DiMethyl Sulfoxide (DMSO) Market to Touch US$ 838.6 Million in 2032 Owing to its Widespread Application in End-Use Industries & Anti-Inflammatory... - September 16th, 2022
- Virology Market Growth Prospects, Trends and Forecast up to 2030 - BioSpace - September 8th, 2022
- Cell Banking Outsourcing Market is Driven by Rising Number of Stem Cell Therapies across the Globe - BioSpace - September 8th, 2022
- Regenerative Therapies Market 2018 By Emerging Trends, Industry Share, Regional Overview and SWOT Analysis till 2026 - Digital Journal - August 22nd, 2022
- Autologous Stem Cell and Non-Stem Cell Based Therapies Market Trends, Competitive Landscape and Regional Insights to 2031 - BioSpace - August 14th, 2022
- Multiphoton Microscopy Market Insights, New Innovations, Research and Growth Factor till 2031 - BioSpace - August 14th, 2022
- Buffalo center fuels research that can save your life from heart disease and stroke - Buffalo News - August 5th, 2022
- Drug Discovery Services Market is Expected to Witness Significant Growth between 20212031 - BioSpace - July 27th, 2022
- Stem Cells Market to Expand at a CAGR of 10.4% from 2021 to 2028 Travel Adventure Cinema - Travel Adventure Cinema - July 27th, 2022
- Dental Membrane and Bone Graft Substitutes Market to Exceed Value of US$ 1,337 Mn by 2031 - PR Newswire UK - July 27th, 2022
- Lipid Disorder Treatment Market is Projected to Experience Promising Growth Opportunities in the Forthcoming Years - BioSpace - July 27th, 2022
- Immunoglobin Products Market to Witness Comprehensive Growth by 2031 - BioSpace - July 19th, 2022
- Antibody Therapy Market Propels at a Robust CAGR of 13.2% due to Rising Cancer and Other Chronic Disease Prevalence Future Market Insights, Inc. -... - July 19th, 2022
- Orthobiologics Market is Predicted to Expand at a CAGR of 4.7% during the Forecast Period, notes TMR Study - GlobeNewswire - July 11th, 2022
- Cell Line Development Market: Increase in Prevalence of Cancer and Other Chronic Diseases to Drive the Market - BioSpace - July 11th, 2022
- Transplant Diagnostic Market: Increase in Number of Cancer & Blood Disorder Patients to Drive the Market - BioSpace - July 11th, 2022
- Microscopy Devices Market Competitive Insights and Precise Outlook 2021-2028 Industrial IT - Industrial IT - June 4th, 2022
- Neoantigen Targeted Therapies Market Analysis and Opportunity Assessment up to 2027 - BioSpace - June 4th, 2022
- Why Eraser Enzymes Go Wrong and Lead to Cancer - SciTechDaily - December 10th, 2021
- MorphoSys and Incyte Announce the European Commission Approval of Minjuvi(R) (tafasitamab) in Combination with Lenalidomide for the Treatment of... - August 31st, 2021
- Incyte and MorphoSys Announce the European Commission Approval of Minjuvi (tafasitamab) in Combination With Lenalidomide for the Treatment of Adults... - August 31st, 2021
- Rock snot discovered in another Pennsylvania waterway - pennlive.com - September 12th, 2020
- Bone Marrow and Stem Cell Transplants ChristianaCare - June 20th, 2020
- 'Billion Dollar Burger' Asks: What Is Meat? - Delaware First Media - June 17th, 2020
- Stem Cell therapy Middletown Delaware 19709 - February 10th, 2020
- First CAR-T cell cancer therapy patient in Delaware - Dover Post - February 10th, 2020
- Gore, Mayo Clinic team up to deliver breakthrough medical therapies - Plastics Today - December 17th, 2019
- Global Stem Cell Therapy Market 2019-2025 Analyzed by Business Growth, Development Factors, Applications, and Future Prospects - Technology Magazine - December 17th, 2019
- From inspiration to innovation | UDaily - UDaily - November 14th, 2019
- What Will Happen to Actinium Pharmaceuticals Inc (delaware (NYSEAMERICAN:ATNM) Next? The Stock Has Increase in Shorts - The Lamp News - October 26th, 2019
- Could Fate Therapeutics, Inc. (FATE) Recover After Forming a Bearish Head & Shoulders Pattern? - The Altcoin Mercury - September 25th, 2019
- Stem Cell therapy Lewes Delaware 19958 - September 14th, 2019
- Westfield High School Principal Derrick Nelson was 'gift ... - May 16th, 2019
- SignalRx - March 22nd, 2019
- Stem Cell therapy Newark Delaware 19725 - February 27th, 2019
- Stem Cell therapy Wilmington Delaware 19810 - February 27th, 2019
- Stem Cell Therapy | Regenerative Delaware - February 22nd, 2019
- Regenerative Cell Treatment &Therapy - Delaware ... - February 22nd, 2019
- Stem Cell Doctors Delaware, Stem cell injections, Stem ... - October 14th, 2018
- Regenerative Cell Therapy - Delaware Integrative Medicine - June 22nd, 2018
- FDA Cracks Down On Stem-Cell Clinics Selling Unapproved Treatments - Delaware First Media - August 30th, 2017
- Detroit Lions' Paul Worrilow has beaten odds, inspires others to help - Detroit Free Press - July 2nd, 2017
- Lions LB Paul Worrilow Making A Difference On And Off The Field - FanRag Sports (blog) - July 2nd, 2017
- Lions LB Paul Worrilow gave stem cells to anonymous leukemia patient - Detroit Free Press - March 11th, 2017
- Delaware (Stem Cell) - what-when-how - November 3rd, 2016
- University of Delaware Chemical Engineering - October 31st, 2015
- Home | www.papoutsakis.org - October 4th, 2015
- Stem Cells - Eppendorf - October 2nd, 2015
- Efficient Differentiation of Mouse Embryonic Stem Cells ... - October 1st, 2015
- Alpine Rose Leaf Extract for Environmental Protection for ... - October 1st, 2015
- De-Differentiation of Somatic Cells to a Pluripotent State ... - June 29th, 2015
- DSU AgDiscovery 2015 - Investing in the Future of American ... - June 1st, 2015
- Stem-cell battles: Stem-cell research in the USA is facing ... - April 9th, 2015
- IPS Stem Cells: New Ethical Quandaries - Santa Clara ... - December 27th, 2014
- The California Cloning and Stem Cell Laws - December 27th, 2014
- Can a bodys own stem cells help heal a heart? - October 19th, 2014
- Delaware Stem Cell Treatment | Stem Cell Treatments - September 9th, 2014
- Core mechanism for root growth identified - August 25th, 2014
- Stem Cell Companies - A Comprehensive Overview - August 23rd, 2014
- Stem Cell Doctors, Physician Team, Our Doctors - August 23rd, 2014
- California Stem Cell Report: California Stem Cell Agency ... - August 23rd, 2014
- Bone Marrow and Stem Cell Transplants - Christiana Care ... - August 22nd, 2014